Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹2,074 Cr
Revenue (TTM)
₹783 Cr
Net Profit (TTM)
₹69 Cr
ROE
10.2 %
ROCE
11.7 %
P/E Ratio
30
P/B Ratio
3.2
Industry P/E
37.31
EV/EBITDA
16.1
Div. Yield
0.2 %
Debt to Equity
0.2
Book Value
₹72.2
EPS
₹8.1
Face value
1
Shares outstanding
88,652,030
CFO
₹522.80 Cr
EBITDA
₹921.16 Cr
Net Profit
₹409.02 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
SMS Pharma
| -1.8 | -12.0 | 11.5 | 8.9 | 48.1 | 33.7 | 17.8 |
|
BSE Healthcare
| -4.7 | 0.8 | 5.0 | 16.9 | 27.0 | 21.6 | 10.3 |
|
BSE Small Cap
| -4.4 | 1.9 | 13.9 | 2.0 | 29.5 | 33.7 | 17.0 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
SMS Pharma
| 99.3 | 43.4 | -35.6 | 8.2 | 183.7 | -41.0 | -34.3 |
|
BSE Small Cap
| 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 | -23.4 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
SMS Pharma
|
234.5 | 2,073.6 | 782.8 | 67.4 | 13.4 | 11.5 | 30 | 3.2 |
| 848.5 | 7,822.7 | 2,115.1 | 272.4 | 17.8 | 14.2 | 28.7 | 3.9 | |
| 1,101.3 | 9,004.4 | 1,006.9 | 160.4 | 20.4 | 12.6 | 56.7 | 6.9 | |
| 544.8 | 8,640.9 | 4,118.2 | 343.8 | 7.6 | 10.7 | 25.6 | 2.8 | |
| 361.5 | 4,442.5 | 1,859.8 | 90.8 | 10.4 | 7.4 | 48.9 | 3.5 | |
| 840.2 | 4,826.1 | 1,243.7 | 128.3 | 13.0 | 13.8 | 37.6 | 5.0 | |
| 1,015.0 | 2,496.2 | 356.3 | 100.9 | 25.0 | 13.3 | 24.7 | 3.2 | |
| 54.8 | 2,098.6 | 488.2 | 70.5 | 17.2 | 13 | 30.2 | 3.5 | |
| 154.5 | 5,030.1 | 71.8 | -342.5 | -467.5 | -- | -- | -23.2 | |
| 935.8 | 2,791.2 | 293.0 | -56.7 | -16.7 | -29.5 | -- | 8.9 |
No Review & Analysis are available.
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, anti-epileptic, anti-psychotic, anti-inflammatory,... anti-fungal, anti-viral, anti-coagulant, and anti-retroviral products. It is also involved in the contract research activities. The company also exports its products. SMS Pharmaceuticals Limited was incorporated in 1987 and is based in Hyderabad, India. Read more
Incorporated
1987
Chairman
Ramesh Babu Potluri
Managing Director
Ramesh Babu Potluri
Headquarters
Hyderabad, Telangana
Website
Looking for more details about SMS Pharmaceuticals Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The total asset value of SMS Pharmaceuticals Ltd stood at ₹ 1,153 Cr as on 31-Mar-25
The share price of SMS Pharmaceuticals Ltd is ₹234.45 (NSE) and ₹235.70 (BSE) as of 20-Jun-2025 14:29 IST. SMS Pharmaceuticals Ltd has given a return of 48.08% in the last 3 years.
SMS Pharmaceuticals Ltd has a market capitalisation of ₹ 2,074 Cr as on 20-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of SMS Pharmaceuticals Ltd is 3.24 times as on 20-Jun-2025, a 8% discount to its peers’ median range of 3.53 times.
The P/E ratio of SMS Pharmaceuticals Ltd is 29.99 times as on 20-Jun-2025, a 20% discount to its peers’ median range of 37.31 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the SMS Pharmaceuticals Ltd and enter the required number of quantities and click on buy to purchase the shares of SMS Pharmaceuticals Ltd.
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, anti-epileptic, anti-psychotic, anti-inflammatory, anti-fungal, anti-viral, anti-coagulant, and anti-retroviral products. It is also involved in the contract research activities. The company also exports its products. SMS Pharmaceuticals Limited was incorporated in 1987 and is based in Hyderabad, India.
The prominent promoters of SMS Pharmaceuticals Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
RAMESH BABU POTLURI |
20.48%
|
|
HIMA BINDU POTLURI |
16.93%
|
|
VAMSI KRISHNA POTLURI |
15.03%
|
|
POTLURI INFRA PROJECTS LLP |
9.98%
|
|
TRILOK POTLURI |
2.47%
|
The chairman of the company is Ramesh Babu Potluri, and the managing director is Ramesh Babu Potluri.
The promoters of SMS Pharmaceuticals Ltd have pledged 24.91% of the total equity as on Mar-25.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
9,040
|
|
|
8,990
|
|
|
8,026
|
|
|
5,384
|
|
|
5,202
|
|
|
4,635
|
|
|
2,868
|
|
|
2,488
|
|
|
2,233
|
| SMS Pharmaceuticals Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
11.49
|
|
Operating margin(%)
|
13.37
|
|
Net Margin(%)
|
8.54
|
|
Dividend yield(%)
|
0.18
|
Yes, TTM profit after tax of SMS Pharmaceuticals Ltd was ₹69 Cr.
₹7.35
(
